Radiotherapy in bladder cancer

Radiotherapy and Oncology

Volumn 52, Issue 1, 1999, Pages 1-14

  Sengeløv, Lisa ^a   Von Der Maase, Hans ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bladder cancer; Chemotherapy; Prognostic factors; Radiotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; VINBLASTINE;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; HEMOGLOBIN DETERMINATION; HUMAN; LYMPH NODE IRRADIATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; REVIEW;

COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; PALLIATIVE CARE; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 0032824054     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(99)00090-0     Document Type: Review

References (122)

1. Abratt R.P., Tucker R.D., Barnes D.R. Radical irradiation of T2 grade III and T3 bladder cancer - tumor response and prognosis. Int. J. Radiat. Oncol. Biol. Phys. 9:1983;1213-1215.
2. Batata M.A., Chu F.C.H., Hilaris B.S., et al. Factors of prognostic and therapeutic significance in patients with bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 7:1981;575-579.
3. Blandy J.P., England H.R., Evans S.J.W., et al. T3 bladder cancer - the case for salvage cystectomy. Br. J. Urol. 52:1980;506-510.
4. Bloom H.J.G., Hendry W.F., Wallace D.M., Skeet R.G. Treatment of T3 bladder cancer: controlled trial of preoperative radiotherapy and radical cystectomy versus radical radiotherapy. Br. J. Urol. 54:1982;136-151.
5. Bretheau D., Ponthieu A. Results of radical cystectomy and pelvic lymphadenectomy for bladder cancer with pelvic node metastases. Urol. Int. 57:1996;27-31.
6. Bydder P.V., Burry A.F., Gowland S., et al. A controlled trial of misonidazole in the curative treatment of infiltrating bladder cancer. Australas. Radiol. 33:1989;8-14.
7. Caffo O., Fellin G., Graffer U., Luciani L. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer. 78:1996;1089-1097.
8. Cervek J., Cufer T., Kragelj B., Zakotnik B., Stanonik M. Sequential transurethral surgery, multiple drug chemotherapy and radiation therapy for invasive bladder carcinoma: initial report. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;777-782.
9. Chauvet B., Brewer Y., Felix-Faure C., Davin J.L., Vincent P., Reboul F. Combined radiation therapy and cisplatin for locally advanced carcinoma of the urinary bladder. Cancer. 72:1993;2213-2218.
10. Christensen E. Multivariate survival analysis using cox regression model. Hepatology. 7:1987;1346-1358.
11. Co-operative Urological cancer group. Prognostic factors in a T3 bladder cancer trial. Br. J. Cancer. 59:1989;441-444.
12. Cohen J.M., Persky L., Resnick M.I. Pattern of urinary symptoms in patients with metastatic bladder cancer. J. Urol. 136:1986;586-588.
13. Concato J., Feinstein A.R., Holford T.R. The risk of determining risk with multivariate models. Ann. Intern. Med. 118:1993;201-210.
14. Coppin C., Gospodarowicz M. The NCI-Canada trial of concurrent cisplatin and radiotherapy for muscle invasive bladder cancer. Prog. Clin. Biol. Res. 353:1990;75-83.
15. Corcoran M.O., Thomas D.M., Lim A., Berry R.J., Milroy E.J. Invasive bladder cancer treated by radical external radiotherapy. Br. J. Urol. 57:1985;40-42.
16. Cox D.R. Regression models and life tables (with discussion). J. R. Statist. Soc. B. 34:1972;187-220.
17. Cox J.D., Guse C., Asbell S., Rubin P., Sause W.T. Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 15:1988;1331-1336.
18. Davidson S.E., Symonds R.P., Snee M.P., Upadhyay S., Habeshaw T., Robertson A.G. Assessment of factors influencing the outcome of radiotherapy for bladder cancer. Br. J. Urol. 66:1990;288-293.
19. de Neve W., Lybeert M.L., Goor C., Crommelin M.A., Ribot J.G. T1 and T2 carcinoma of the urinary bladder: long term results with external, preoperative, or interstitial radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23:1992;299-304.
20. Dershaw D.D., Panicek D.M. Imaging of invasive bladder cancer. Semin. Oncol. 17:(5):1990;544-550.
21. Duncan W., Quilty P.M. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother. Oncol. 7:1986;299-310.
22. Dunst J., Sauer R., Schrott K.M., Kuhn R., Wittekind C., Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;261-266.
23. Edsmyr F., Andersson L., Esposti P.L., Littbrand B., Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Rad. Oncol. 4:1985;197-203.
24. Einstein A.B. Jr, Wolf M., Halliday K.R. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study. Urology. 47:1996;652-6547.
25. Farah R., Chodak G.W., Vogelzang N.J., et al. Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int. J. Radiat. Oncol. Biol. Phys. 20:1991;413-417.
26. Fellin G., Graffer U., Bolner A., Ambrosini G., Caffo O., Luciani L. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br. J. Urol. 80:1997;44-49.
27. Abrahamsen Foss, Fosså J. S.D. Long-term morbidity after curative radiotherapy for carcinoma of the bladder. Strahlenther. Onkol. 166:1990;580-583.
28. Fosså S.D., Hosbach G. Short-term moderate-dose pelvic radiotherapy of advanced bladder carcinoma. A questionnaire-based evaluation of its symptomatic effect. Acta Oncol. 30:1991;735-738.
29. Fosså S.D., Ous S., Espetveit S., Landmark F. Patterns of primary care and survival in 336 consecutive unselected Norwegian patients with bladder cancer. Scand. J. Urol. Nephrol. 26:1992;131-138.
30. Fosså S.D., Ous S., Knudsen O.S. Radical irradiation of T2 and T3 bladder carcinoma. Acta Radiol. Oncol. 24:1985;497-501.
31. Fosså S.D., Waehre H., Aass N., Jacobsen A.B., Olsen D.R., Ous S. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer. 72:1993;3036-3043.
32. Fowler J.F. Modelling altered fractionation schedules. Br. J. Radiol. 24:1992;187-192.
33. Fung C.Y., Shipley W.U., Young R.H., et al. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J. Clin. Oncol. 9:(9):1991;1533-1542.
34. Ghersi D., Stewart L.A., Parmar M.K.B., et al. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaboration. Br. J. Urol. 75:1995;206-213.
35. Given R.W., Parsons J.T., McCarley D., Wajsman Z. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology. 46:1995;499-505.
36. Goffinet D.R., Schneider M.J., Glatstein E.J., et al. Bladder cancer: results of radiation therapy in 384 patients. Radiology. 117:1975;149-153.
37. Goodman G.B., Hislop T.G., Elwood J.M., Balfour J. Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selective cystectomy. Int. J. Radiat. Oncol. Biol. Phys. 7:1981;569-573.
38. Gospodarowicz M.K., Hawkins N.V., Rawlings G.A., Eta L. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J. Urol. 142:1989;1448-1454.
39. Granfors T., Duchek M., Tomic R., Roos G., Ljungberg B. Predictive value of DNA ploidy in bladder cancer treated with preoperative radiation therapy and cystectomy. Scand. J. Urol. Nephrol. 30:1996;281-285.
40. Greven K.M., Solin L.J., Hanks G.E. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer. 65:1990;908-912.
41. Gschwend J.E., May F., Paiss T., Gottfried H.W., Hautmann R.E. High-dose pelvic irradiation followed by ileal neobladder urinary diversion: complications and long-term results. Br. J. Urol. 77:1996;680-683.
42. Hall R.R, for MRC, EORTC GU Group, et al. Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC intercontinental trial [abstract]. Proc. Am. Soc. Clin. Oncol. 1996;15:244.
43. Herr H.W. Conservative management of muscle infiltrating bladder cancer: prospective experience. J. Urol. 138:1987;1162-1163.
44. Holmang S., Borghede G. Early complications and survival following short-term palliative radiotherapy in invasive bladder carcinoma. J. Urol. 155:1996;100-102.
45. Hopkins H.A., Looney W.B. Solid tumor models for the assessment of different treatment modalities: XXVI. Estimates of cell survival from tumor growth delay after alternating radiotherapy and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 13:1987;217-224.
46. Hoskin P.J., Saunders M.I., Phillips H., et al. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br. J. Cancer. 76:1997;260-263.
47. Housset M., Maulard C., Chretien Y., et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J. Clin. Oncol. 11:1993;2150-2157.
48. Hug E.B., Donnelly S.M., Shipley W.U., et al. Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy. J. Urol. 148:1992;47-51.
49. Huncharek M., Muscat J., Geschwind J.F. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res. 18:1998;1931-1934.
50. Jahnson S., Pedersen J., Westman G. Bladder carcinoma - a 20-year review of radical irradiation therapy. Radiother. Oncol. 22:1991;111-117.
51. Jahnson S., Risberg B., Karlsson M.G., Westman G., Bergstrom R., Pedersen J. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur. Urol. 28:1995;135-142.
52. Jakse G., Zur N.D., Hellweg G., Fritsch E., Frommhold H. Evaluation of tumor response in patients with bladder cancer undergoing combined radiotherapy and chemotherapy. Eur. Urol. 17:1990;286-288.
53. Jenkins B.J., Caulfield M.J., Fowler C.G., et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br. J. Urol. 62:1988;343-346.
54. Jenkins B.J., Martin J.E., Baithun S.I., Zuk R.J., Oliver R.T., Blandy J.P. Prediction of response to radiotherapy in invasive bladder cancer. Br. J. Urol. 65:1990;345-348.
55. Kamby C., Sengeløv L. Assessment of functional status in patients with invasive carcinoma of the urothelial tract. Urol. Oncol. 2:1996;43-51.
56. Kaufman D.S., Shipley W.U., Griffin P.P., Heney N.M., Althausen A.F., Efird J.T. Selective bladder preservation by combination treatment of invasive bladder cancer. N. Engl. J. Med. 329:1993;1377-1382.
57. Larsen L.E., Engelholm S.A. The value of three-dimensional radiotherapy planning in advanced carcinoma of the urinary bladder based on computed tomography. Acta Oncol. 33:1994;655-659.
58. Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. J. Clin. Oncol. 10:1992;1066-1073.
59. Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. J. Clin. Oncol. 10:1992;1066-1073.
60. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8:(6):1990;1050-1055.
61. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8:(6):1990;1050-1055.
62. Lynch W.J., Jenkins B.J., Fowler C.G., Hope-Stone H.F., Blandy J.P. The quality of life after radical radiotherapy for bladder cancer. Br. J. Urol. 70:1992;519-521.
63. Maciejewski B., Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother. Oncol. 21:1991;163-170.
64. Malmstrom P.U., Rintala E., Wahlqvist R., Hellstrom P., Hellsten S., Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J. Urol. 155:1996;1903-1906.
65. Marcial V.A., Amato D.A., Brady L.W., et al. Split-course radiotherapy of carcinoma of the urinary bladder stages C and D1. A Radiation Therapy Oncology Group Study. Am. J. Clin. Oncol. 8:1985;185-199.
66. McLaren D.B., Morrey D., Mason M.D. Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother. Oncol. 43:1997;171-174.
67. Moonen L.M., Horenblas S., van der Voet J.C., Nuyten M.J., Bartelink H. Bladder conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using combination therapy of surgery and iridium-192 implantation. Br. J. Urol. 74:1994;322-327.
68. Moonen L.M. Voet. H.v.d., de Nijs, R., Horenblas, S., Hart, A.A.M., Bartelink, H. Muscle-invasive bladder cancer treated with external beam radiation: Influence of total dose, overall treatment time, and treatment interruption on local control. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;525-530.
69. Moore M.J., O'Sullivan B., Tannock I.F. How expert physicians would wish to be treated if they had genitourinary cancer. J. Clin. Oncol. 6:1988;1736-1745.
70. Naslund I., Nilsson B., Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol. 33:1994;397-402.
71. Ogura K., Habuchi T., Yamada H., Ogawa O., Yoshida O. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. Int. J. Urol. 2:1995;302-308.
72. Orovan W.L., Davis I.R. Urinary diversion using the Kock ileal reservoir in patients with irradiated bowel. Can. J. Surg. 31:1988;243-245.
73. Overgaard J. Vendelbo Johansen. L., Hjelm-Hansen, M., Andersen, A.P. Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol. 27:1988;147-152.
74. Parsons J.T., Million R.R. Role of planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma in the 1980s. Semin. Surg. Oncol. 5:1989;255-265.
75. Pollack A., Czerniak B., Zagars G.K., et al. Retinoblastoma protein expression and radiation response in muscle- invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;687-695.
76. Pollack A., Zagars G.K., Swanson D.A. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;267-277.
77. Prout G.R., Griffin P.P., Shipley W.U., Eta L. Bladder carcinoma as a systemic disease. Cancer. 43:1979;2532-2539.
78. Prout G.R.J., Shipley W.U., Kaufman D.S., et al. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J. Urol. 144:1990;1128-1134.
79. Quilty P.M., Duncan W. Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;853-860.
80. Quilty P.M., Duncan W., Chisholm G.D., et al. Results of surgery following radical radiotherapy for invasive bladder cancer. Br. J. Urol. 58:1985;396-405.
81. Richards B., Bastable J.R.G., Freedman L., et al. Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3,NX,MO bladder cancer treated with radiotherapy. Br. J. Urol. 55:1983;386-391.
82. Rintala E., Hannisdahl E., Fosså S.D., Hellsten S., Sander S. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand. J. Urol. Nephrol. 27:1993;355-362.
83. Rostom A.Y., Tahir S., Gershuny A.R., Kandil A., Folkes A., White W.F. Once weekly irradiation for carcinoma of the bladder. Int. J. Radiat. Oncol. Biol. Phys. 35:1996;289-292.
84. Rozan R., Albuisson E., Donnarieix D., et al. Interstitial iridium-192 for bladder cancer (a multicentric survey: 205 patients). Int. J. Radiat. Oncol. Biol. Phys. 24:1992;469-477.
85. Salmien E. External beam radiation treatment of urinary bladder carcinoma. Acta Oncol. 29:1990;909-914.
86. Salminen E. Split-course radiotherapy for urinary bladder cancer. Radiother. Oncol. 15:1989;327-331.
87. Salminen E. Unconventional fractionation for palliative radiotherapy of urinary bladder cancer. A retrospective review of 94 patients. Acta Oncol. 31:1992;449-454.
88. Sauer R., Birkenhake S., Kuhn R., Wittekind C., Schrott K.M., Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 40:1998;121-127.
89. Scher H.I., Herr H.W., Sternberg C.N., et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br. J. Urol. 64:1989;250-256.
90. Scholten A.N., Leer J.W., Collins C.D., Wondergem J., Hermans J., Timothy A. Hypofractionated radiotherapy for invasive bladder cancer. Radiother. Oncol. 43:1997;163-169.
91. Sell A., Jakobsen A., Nerstrom B., Sorensen B.L., Steven K., Barlebo H. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand. J. Urol. Nephrol. 138:1991;193-201.
92. Sengeløv L., Klintorp S., Havsteen H., Kamby C., Hansen S.L., von der Maase H. Treatment outcome following radiotherapy in elderly patients with bladder cancer. Radiother. Oncol. 44:1997;53-58.
93. Shetata W.M., Meyer R.L., Costandi Y.T. Curative and palliative radiotherapy of bladder cancer. Radiology. 146:1983;523-526.
94. Shipley W.U., Prout G.R., Einstein A.B., et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. J. Am. Med. Assoc. 258:1987;931-935.
95. Shipley W.U., Prout G.R.J., Kaufman D.S., Perrone T.L. The importance of transurethral surgery and other significant prognostic factors for improved survival with full dose irradiation. Cancer. 60:1987;514-520.
96. Shipley W.U., Rose M.A., Perrone T.L., Mannix C.M., Heney N.M., Prout G.R.J. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J. Urol. 134:1985;679-683.
97. Shipley W.U., Winter K.A., Lee R., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J. Clin. Oncol. 16:1998;3576-3583.
98. Skinner D.G. Current perspectives in the management of high-grade invasive bladder cancer. Cancer. 45:1980;1866-1874.
99. Skinner D.G., Daniels J.R., Russel C.A., et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 145:1991;459-467.
100. Smith J.A.J., Crawford E.D., Paradelo J.C., et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J. Urol. 157:1997;805-807.
101. Sternberg C.N. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin. Oncol. 23:1996;621-632.
102. Stuschke M., Thames H.D. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;259-267.
103. Stöckle M., Meyenburg W., Wellek S., et al. Advanced bladder cancer (stages pT3b, pT4a, pN1, and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 148:1992;302-307.
104. Stöckle M., Meyenburg W., Wellek S., et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol. 153:1995;47-52.
105. Sur R.K., Clinkard J., Jones W.G., et al. Changes in target volume during radiotherapy treatment of invasive bladder carcinoma. Clin. Oncol. (R. Coll. Radiol). 5:1993;30-33.
106. Tait D.M., Nahum A.E., Meyer L.C., et al. Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother. Oncol. 42:1997;121-136.
107. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J. Clin. Oncol. 14:1996;119-126.
108. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;783-790.
109. Thames H.D.J., Withers H.R., Peters L.J., Fletcher G.H. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int. J. Radiat. Oncol. Biol. Phys. 8:1982;219-226.
110. Tjonneland A., Skov T., Mellemgaard A. Survival of Danish cancer patients 1943-1987. Urinary tract. Apmis; 33:1993;137-148.
111. Tomic R., Granfors T., Modig H. Morbidity after preoperative radiotherapy and cystectomy in patients with bladder cancer. Scand. J. Urol. Nephrol. 31:1997;149-153.
112. Turner S.L., Swindell R., Bowl N., et al. Bladder movement during radiation therapy for bladder cancer: implications for treatment planning. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;355-360.
113. Vale J.A., A'Hern R.P., Liu K., et al. Predicting the outcome of radical radiotherapy for invasive bladder cancer. Eur. Urol. 24:1993;48-51.
114. von der Maase H. Complications of combined radiotherapy and chemotherapy. Semin. Radiat. Oncol. 4:1994;81-94.
115. Vrouvas J., Dodwell D., Ash D., Probst H. Split course radiotherapy for bladder cancer in elderly unfit patients. Clin. Oncol. (R. Coll. Radiol.). 7:1995;193-195.
116. Wallace D.M., Bloom H.J. The management of deeply infilrating (T3) bladder carcinoma: controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report). Br. J. Urol. 48:1976;587-594.
117. Whillis D., Howard G.C., Kerr G.R., Fowler J., Hargreave T.B., Chisholm G.D. Radical radiotherapy with salvage surgery for invasive bladder cancer: results following a reduction in radiation dose. J. R. Coll. Surg. Edinb. 37:1992;42-45.
118. Wijkstrom H., Edsmyr F., Nilsson B. Treatment of invasive grade 3 transitional cell bladder cancer. A retrospective study of 10 years' experience with external irradiation, and preoperative irradiation and cystectomy. Eur. Urol. 13:1987;300-304.
119. Wijkstrom H., Naslund I., Ekman P., Kohler C., Nilsson B., Norming U. Short-term radiotherapy as palliative treatment in patients with transitional cell bladder cancer. Br. J. Urol. 67:1991;74-78.
120. Wijnmaalen A., Helle P.A., Koper P.C., Jansen P.P., Hanssens P.E., Boeken K.C., et al. Muscle invasive bladder cancer treated by transurethral resection, followed by external beam radiation and interstitial iridium-192. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;1043-1052.
121. Wu C.S., Pollack A., Czerniak B., Chyle V., Zagars G.K., Dinney C.P., et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology. 47:1996;305-310.
122. Yu W.S., Sagerman R.H., Chung C.T., Dalal P.S., King G.A. Bladder carcinoma. Experience with radical and preoperative radiotherapy in 421 patients. Cancer. 56:1985;1293-1299.